SARS-CoV-2 Spike glycoprotein (ChAdOx1-S)
Also known as: AZD1222 ChAdOx1 nCoV-19 COVID-19 Vaccine AstraZeneca
Therapeutic Indications
SARS-CoV-2 Spike glycoprotein (ChAdOx1-S) is indicated for:
Active immunisation to prevent COVID-19 caused by SARS-CoV-2
Irrespective of gender only Adults (18 years old or older)
SARS-CoV-2 Spike glycoprotein (ChAdOx1-S) is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older.
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Intramuscular - 0.5 ml once
Contraindications
Active ingredient SARS-CoV-2 Spike glycoprotein (ChAdOx1-S) is contraindicated in the following cases: